Grundläggande statistik
| CIK | 1674657 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Motif Bio plc ADRs
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| March 26, 2020 |
MTFB / Motif Bio plc ADRs 15-12B - - FORM 15-12B 15-12B 1 f1512b032620.htm FORM 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-37847 MOTIF BIO PLC (Exact name o |
|
| March 18, 2020 |
Motif Bio plc ("Motif Bio" or the "Company") Corporate Update Exhibit 99.1 18 March 2020 Motif Bio plc ("Motif Bio" or the "Company") Corporate Update Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, provides an update on corporate developments. As announced on 28 January 2020, Motif Inc. ceased all operations and engaged Tamarack Associates to facilitate the sale of iclaprim and other assets of Motif Inc. It remains the c |
|
| March 18, 2020 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: March 2020 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| March 5, 2020 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: March 2020 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| January 29, 2020 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: January 2020 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal ex |
|
| January 29, 2020 |
Exhibit 99.1 28 January 2020 Motif Bio plc ("Motif Bio" or the "Company") Corporate Update Agreement with Hercules Capital, Inc Reclassification as a Rule 15 Cash Shell Motif Bio plc (AIM/Nasdaq: MTFB) today provided an update on recent corporate developments following the General Meeting held on 14 November 2019 (the “General Meeting”). Agreement with Hercules Capital, Inc The Company and its who |
|
| December 23, 2019 |
MTFB / Motif Bio plc ADRs POS AM - - POS AM As filed with the Securities and Exchange Commission on December 23, 2019 Registration No. |
|
| December 23, 2019 |
MTFB / Motif Bio plc ADRs POS AM - - POS AM As filed with the Securities and Exchange Commission on December 23, 2019 Registration No. |
|
| December 9, 2019 |
MTFB / Motif Bio plc ADRs 25 - - FORM 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37847 MOTIF BIO PLC The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 125 Park Ave |
|
| November 27, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: November 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal e |
|
| November 27, 2019 |
EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 27 November 2019 Motif Bio plc ("Motif Bio" or the "Company") American Depositary Shares (“ADS”) Program and Warrant Agent Agreement Motif Bio plc (AIM/Nasdaq: MTFB) announces, that further to the announcement yesterday of the Company’s intention to voluntarily delist its American Depository Shares (ADSs), it has given notice on November 26, 2019 to T |
|
| November 26, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive |
|
| November 26, 2019 |
Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares (ADSs |
|
| November 18, 2019 |
Motif Bio plc ("Motif Bio" or the "Company") Directorate Changes Exhibit 99.1 18 November 2019 Motif Bio plc ("Motif Bio" or the "Company") Directorate Changes Motif Bio plc (AIM/Nasdaq: MTFB) announces that the following Non-Executive Directors have offered their resignations as of the close of business US time on Friday 15 November 2019 and will stand down from the board with immediate effect: Dr. Craig Albanese, Charlotta Ginman, Zaki Hosny, Dr. Mary Lake Po |
|
| November 18, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: November 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal e |
|
| November 15, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: November 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal e |
|
| November 15, 2019 |
Motif Bio plc ("Motif Bio" or the "Company") Result of General Meeting EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 14 November 2019 Motif Bio plc ("Motif Bio" or the "Company") Result of General Meeting Motif Bio plc (AIM/Nasdaq: MTFB announces that at the General Meeting (“GM”) of the Company held earlier today in New York, all resolutions put to shareholders were duly passed. The results of the poll, incorporating the proxy votes lodged in advance of the meeting |
|
| November 12, 2019 |
Motif Bio plc ("Motif Bio" or the "Company") Settlement Agreement Exhibit 99.1 11 November 2019 Motif Bio plc ("Motif Bio" or the "Company") Settlement Agreement Motif Bio plc (AIM/Nasdaq: MTFB) announces that its subsidiary Motif BioSciences Inc., has reached agreement with its former clinical research organisation to settle all obligations without further payment. This will result in the reversal of a previously recognised expense and the reduction of the Moti |
|
| November 12, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: November 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal e |
|
| October 28, 2019 |
MTFB / Motif Bio plc ADRs / Invesco Ltd. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (AMENDMENT NO. 5) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0.01 per share (Title of Class of Securities) 619784101 (CUSIP Number) Nancy Tomassone Invesco Ltd. 1555 Peachtree Street, N.E., Suite 1800 Atlanta, Georgia 30309 Telephone Number: (404) 892-0896 |
|
| October 25, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: October 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal ex |
|
| October 25, 2019 |
Motif Bio plc ("Motif Bio" or the "Company") Posting of Circular and Notice of General Meeting Exhibit 99.1 25 October 2019 Motif Bio plc ("Motif Bio" or the "Company") Posting of Circular and Notice of General Meeting Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcements of 2 October 2019 and 21 October 2019, confirmed today that a Circular incorporating a formal Notice of General Meeting (‘Ge |
|
| October 3, 2019 |
Motif Bio plc (“Motif Bio”, or “the Company”) Change of Adviser Exhibit 99.1 3 October 2019 Motif Bio plc (“Motif Bio”, or “the Company”) Change of Adviser Motif Bio plc (AIM/NASDAQ: MTFB) is pleased to announce the appointment of SP Angel Corporate Finance LLP as nominated adviser and sole corporate broker with immediate effect. AIM Rule 17 Disclosure In accordance with AIM Rule 17 and Schedule Two (g) sub-paragraph (v) of the AIM Rules for Companies (the “AI |
|
| October 3, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 f6k100319.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: October 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 1 |
|
| October 2, 2019 |
EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 2 October 2019 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. NOT FOR RE |
|
| October 2, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 f6k100219.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: October 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 1 |
|
| September 30, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: September 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal |
|
| September 30, 2019 |
Exhibit 99.1 September 30, 2019 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Motif Bio plc (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to the Form 6-K of Motif Bio plc dated September 30, 2019. We agree with the statements concerning our Firm contained there |
|
| September 30, 2019 |
Exhibit 99.1 30 September 2019 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. Motif Bio plc and subsidiary (“Motif Bio”, or “the Group”) Motif Bio Reports Half-Year 2019 Financial Results, Operational Progress and Proposed |
|
| September 30, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: September 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal |
|
| September 3, 2019 |
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT EX-99.2 3 exh992.htm PRESS RELEASE EXHIBIT 99.2 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “FifthAmendment”) is made as of this 30th day of August 2019, by and between MOTIF BIOSCIENCES INC., a Delaware corporation (“Borrower”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral age |
|
| September 3, 2019 |
Motif Bio and Hercules Capital Amend Loan and Security Agreement EXHIBIT 99.1 Motif Bio and Hercules Capital Amend Loan and Security Agreement NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that its lender, Hercules Capital, Inc. (“Hercules”), has agreed to amend the Company’s loan and security agreemen |
|
| September 3, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 September 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive office) Indicat |
|
| August 1, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive o |
|
| August 1, 2019 |
Motif Bio and Hercules Capital Amend Loan and Security Agreement EXHIBIT 99.1 Motif Bio and Hercules Capital Amend Loan and Security Agreement NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its Lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortization date |
|
| August 1, 2019 |
FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Fourth Amendment”) is made as of this 30th day of July 2019, by and between MOTIF BIOSCIENCES INC., a Delaware corporation (“Borrower”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral ag |
|
| July 26, 2019 |
Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim EXHIBIT 99.1 Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type B meeting related to a proposed clinical study f |
|
| July 26, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive off |
|
| July 26, 2019 |
Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has received a deficiency notice from Nasdaq indicating that, based upon a review of Motif Bio’s tradi |
|
| July 26, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive off |
|
| July 19, 2019 |
Motif Bio Announces Receipt of Deficiency Notice from Nasdaq EXHIBIT 99.1 Motif Bio Announces Receipt of Deficiency Notice from Nasdaq NEW YORK, July 19, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has received a deficiency notice from Nasdaq indicating that, based upon a review of Motif Bio’s Market Value of Listed Securities (MVLS |
|
| July 19, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 f6k071919.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: July 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Addr |
|
| July 15, 2019 |
Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim EXHIBIT 99.1 Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim NEW YORK, July 15, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has submitted a meeting request and package to the U.S. Food & Drug Administration (FDA) related to the Company’s lead pro |
|
| July 15, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive off |
|
| June 6, 2019 |
EXHIBIT 99.1 Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes Conference call scheduled for Thursday, June 6, 2019 at 8:00 AM EDT/1:00 PM BST/2:00 PM CET NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has recei |
|
| June 6, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive off |
|
| May 31, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: May 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive off |
|
| May 31, 2019 |
Result of Annual General Meeting EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Result of Annual General Meeting NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting held earlier today, all but one of the resolutions proposed were duly passed by the shareholders on a poll. T |
|
| May 22, 2019 |
EXHIBIT 99.1 Motif Bio plc AGM Statement NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier today the Company provided the following review of key aspects of its business and growth strategy. Iclaprim for treating ABSSSI (acute bacterial |
|
| May 22, 2019 |
MTFB / Motif Bio plc ADRs 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive offi |
|
| May 3, 2019 |
MTFB / Motif Bio plc ADRs 6-K Current Report of Foreign Issuer FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal executive offi |
|
| May 3, 2019 |
Motif Bio meeting with U.S. FDA held as planned EXHIBIT 99.1 Motif Bio meeting with U.S. FDA held as planned NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met with the U.S. Food & Drug Administration (FDA) on May 3, 2019 as expected. The Type A meeting was held to discuss the points raised in the Compl |
|
| April 26, 2019 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: April 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| April 26, 2019 |
EXHIBIT 99.4 MOTIF BIO PLC Proxy Form I/We, (insert full name in BLOCK CAPITALS) of (insert address in BLOCK CAPITALS) POSTCODE being (a) holder(s) of ordinary shares in Motif Bio plc appoint the Chairman of the meeting or the following person: Name Number of Shares as my/our proxy to attend, speak and vote for me/us and on my/our behalf at the Annual General Meeting of the Company to be held at 1 |
|
| April 26, 2019 |
EXHIBIT 99.5 Dear Shareholder, NOTICE OF AGM / ANNUAL REPORT & ACCOUNTS We hereby notify you that the Annual Report and Financial Statements for the year ended 2018, Notice of the Annual General Meeting to be held on 22 May 2019, and the form of proxy for the Annual General Meeting are now available on the Company’s website www.motifbio.com under the tab https://www.motifbio.com/aim-investors/. Yo |
|
| April 26, 2019 |
Motif Bio Announces Appointment of Andrew Powell to Board of Directors EXHIBIT 99.1 Motif Bio Announces Appointment of Andrew Powell to Board of Directors NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately. Mr. Powell ha |
|
| April 26, 2019 |
Motif Bio plc: Notice of Annual General Meeting EXHIBIT 99.2 Motif Bio plc: Notice of Annual General Meeting NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) - Motif Bio plc ("Motif Bio" or the "Company") (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its notice of its Annual General Meeting (AGM) have been posted to shareholders and will shortly be available for downlo |
|
| April 26, 2019 |
EXHIBIT 99.3 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to seek financial advice from your stockbroker or other independent adviser authorized under the Financial Services and Market Act 2000 (as amended). If you have recently sold or transferred all of your shares in Motif Bio plc, please forward |
|
| April 15, 2019 |
MTFB / Motif Bio plc ADRs 20-F 20-F 1 a19-2933120f.htm 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUA |
|
| April 15, 2019 |
CONSENT OF BAL PHARMA CONSULTING, LLC Exhibit 15.2 CONSENT OF BAL PHARMA CONSULTING, LLC BAL Pharma Consulting, LLC hereby consents to all references to the market research survey it was commissioned to prepare on behalf of Motif Bio plc entitled “Assessment of Iclaprim Commercial Opportunity in the Gram Positive Antibiotic Hospital Market” and to the results of such survey (collectively, the “BAL Information”) included in this Annual |
|
| April 15, 2019 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (Nos. 333-222042, 333-222614) of Motif Bio plc of our report dated April 15, 2019 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LLP Florham Park, New Jersey April 15, 2019 |
|
| April 15, 2019 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Motif Bio plc (the “Company”) on Form 20-F for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof, I, Jonathan Gold Chief Financial |
|
| April 15, 2019 |
Exhibit 15.3 CONSENT OF JMI LABORATORIES JMI Laboratories hereby consents to all references to the worldwide microbiological survey (protocol #15-MOT-01) it was commissioned to prepare on behalf of Motif Bio plc and to the results of such survey (collectively, the “JMI Information”) included in this Annual Report on Form 20-F of Motif Bio plc for the year ending December 31, 2018, and to all refer |
|
| April 15, 2019 |
Exhibit 15.4 CONSENT OF IHMA LABORATORIES IHMA Laboratories hereby consents to all references to the US and Europe microbiological survey it was commissioned to prepare on behalf of Motif Bio plc and to the results of such survey (collectively, the “IHMA Information”) included Annual Report on Form 20-F of Motif Bio plc for the year ending December 31, 2018, and to all references to IHMA Laborator |
|
| April 15, 2019 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jonathan Gold, certify that: 1. I have reviewed this annual report on Form 20-F of Motif Bio plc (the “Company”) or the fiscal year ended December 31, 2018; 2. Based on my knowledge, this annual repor |
|
| April 15, 2019 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Dr. Graham Lumsden, certify that: 1. I have reviewed this annual report on Form 20-F of Motif Bio plc (the “Company”) or the fiscal year ended December 31, 2018; 2. Based on my knowledge, this annual |
|
| April 15, 2019 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Motif Bio plc (the “Company”) on Form 20-F for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof, I, Dr. Graham Lumsden, Chief Exec |
|
| April 15, 2019 |
Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio Reports Fiscal Year 2018 Results Exhibit 99.1 April 15, 2019 Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio Reports Fiscal Year 2018 Results Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2018. Dr. Graham Lumsden, Chief Executive Officer, said: “Motif Bio had an incredibly productiv |
|
| April 15, 2019 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: April 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| April 15, 2019 |
Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio Reports Fiscal Year 2018 Results Exhibit 99.2 15 April 2019 Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio Reports Fiscal Year 2018 Results Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2018. Dr. Graham Lumsden, Chief Executive Officer, said: “Motif Bio had an incredibly productive |
|
| April 2, 2019 |
MTFB / Motif Bio plc ADRs / Invesco Ltd. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (AMENDMENT NO. 4) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0.01 per share (Title of Class of Securities) 619784101 (CUSIP Number) Nancy Tomassone Invesco Ltd. 1555 Peachtree Street, N.E., Suite 1800 Atlanta, Georgia 30309 Telephone Number: (404) 892-0896 |
|
| March 26, 2019 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: March 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| March 26, 2019 |
Motif Bio plc ("Motif Bio" or the "Company") Motif Bio Raises £2.7m (US$3.55m) Exhibit 99.1 26 March 2019 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, |
|
| March 26, 2019 |
Exhibit 99.2 |
|
| March 25, 2019 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: March 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| March 25, 2019 |
Motif Bio plc ("Motif Bio" or the "Company") Proposed Equity Fundraise Exhibit 99.1 25 March 2019 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Motif Bio plc ("Motif Bio" or the "Company") |
|
| March 20, 2019 |
Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim EXHIBIT 99.1 Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type A meeting to discuss the points raised in the Complet |
|
| March 20, 2019 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Address of principal executive o |
|
| March 18, 2019 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k031819.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Add |
|
| March 18, 2019 |
EXHIBIT 99.1 Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and |
|
| February 19, 2019 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: February 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal e |
|
| February 19, 2019 |
Motif BioSciences Enters into Amendment Agreement with Hercules Capital EXHIBIT 99.1 Motif BioSciences Enters into Amendment Agreement with Hercules Capital NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif BioSciences Inc. (a wholly owned subsidiary) has entered into an amendment agreement with its lender Hercules Capital, Inc |
|
| February 19, 2019 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT EXHIBIT 99.2 Execution Version SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is made this 17th day of February, 2019, by and between MOTIF BIOSCIENCES INC., a Delaware corporation (“Borrower”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the L |
|
| February 15, 2019 |
MTFB / Motif Bio plc ADRs / Invesco Ltd. - MOTIF BIO PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (AMENDMENT NO. 3) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0.01 per share (Title of Class of Securities) 619784101 (CUSIP Number) Nancy Tomassone Invesco Ltd. 1555 Peachtree Street, N.E., Suite 1800 Atlanta, Georgia 30309 Telephone Number: (404) 892-0896 |
|
| February 14, 2019 |
Motif Bio Receives Complete Response Letter from the FDA EXHIBIT 99.1 Motif Bio Receives Complete Response Letter from the FDA NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (ND |
|
| February 14, 2019 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2019 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Address of principal executiv |
|
| February 13, 2019 |
MTFB / Motif Bio plc ADRs / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Motif Bio plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 619784101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 11, 2019 |
MTFB / Motif Bio plc ADRs / Invesco Ltd. - MOTIF BIO PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (AMENDMENT NO. 2) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0.01 per share (Title of Class of Securities) 619784101 (CUSIP Number) Nancy Tomassone Invesco Ltd. 1555 Peachtree Street, N.E., Suite 1800 Atlanta, Georgia 30309 Telephone Number: (404) 892-0896 |
|
| February 5, 2019 |
MTFB / Motif Bio plc ADRs / M&G INVESTMENT MANAGEMENT LTD - MOTIF BIO PLC Passive Investment SC 13G 1 d625312dsc13g.htm MOTIF BIO PLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Motif Bio plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) G62924108 (CUSIP Number) 31st December 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| September 25, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: September 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal |
|
| September 25, 2018 |
Exhibit 99.1 25 September 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. Motif Bio plc and subsidiary (“Motif Bio”, or “the Group”) Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress Motif Bio |
|
| August 21, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: August 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exe |
|
| August 21, 2018 |
Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio notes statement from Amphion Innovations Exhibit 99.1 21 August 2018 Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio notes statement from Amphion Innovations Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement made today via RNS by Amphion Innovations plc (“Amphion”), a substantial shareholder in the Company, relating to its sale of share |
|
| August 14, 2018 |
EXHIBIT 99.1 Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections PDUFA action date set for February 13, 2019 NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced |
|
| August 14, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k081418.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: August 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (A |
|
| August 8, 2018 |
Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037 EXHIBIT 99.1 Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037 NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received a Notice of Allowance from the United States Paten |
|
| August 8, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Address of principal executive |
|
| July 3, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Address of principal executive of |
|
| July 3, 2018 |
Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors EXHIBIT 99.1 Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has informed the Company of his decision to resign from the Board of Directors, effective July 16, 2018 |
|
| June 19, 2018 |
Motif Bio plc (“Motif Bio” or the “Company”) Result of Annual General Meeting Exhibit 99.1 19 June 2018 Motif Bio plc (“Motif Bio” or the “Company”) Result of Annual General Meeting Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting held earlier today, all resolutions proposed were duly passed by the shareholders on a poll. The results of the poll, incorporat |
|
| June 19, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) 6-K 1 a18-1562416k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 |
|
| June 14, 2018 |
Motif Bio Submits NDA for Iclaprim EXHIBIT 99.1 Motif Bio Submits NDA for Iclaprim NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for iclaprim, a targeted, Gram-positive invest |
|
| June 14, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Address of principal executive o |
|
| May 23, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: May 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal execut |
|
| May 23, 2018 |
Motif Bio plc ("Motif Bio" or the "Company") Motif Bio notes statement from Amphion Innovations Exhibit 99.1 23 May 2018 Motif Bio plc ("Motif Bio" or the "Company") Motif Bio notes statement from Amphion Innovations Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement made today via RNS by Amphion Innovations plc ("Amphion"), a substantial shareholder in the Company, relating to its sale of shares i |
|
| May 17, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: May 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal execut |
|
| May 17, 2018 |
Motif Bio plc (“Motif Bio” or the “Company”) Proposed Placing to raise approximately £10m (US$14m) Exhibit 99.1 17 May 2018 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, D |
|
| May 17, 2018 |
Motif Bio plc (“Motif Bio” or the “Company”) Result of Placing Exhibit 99.2 17 May 2018 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, D |
|
| May 9, 2018 |
Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development EXHIBIT 99.1 Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Stephanie Noviello, MD, MPH has joined the Company as Vice President, Clinical Development. She will report |
|
| May 9, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k050818.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Addre |
|
| April 19, 2018 |
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018 EXHIBIT 99.1 Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018 NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) - Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI Data continue to support iclaprim activity against MRSA and other drug-resistant pathogens Motif Bio plc (AI |
|
| April 19, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k041918.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Add |
|
| April 17, 2018 |
Exhibit 99.5 MOTIF BIO PLC Proxy Form I/We, (insert full name in BLOCK CAPITALS) of (insert address in BLOCK CAPITALS) POSTCODE being (a) holder(s) of ordinary shares in Motif Bio plc appoint the Chairman of the meeting or the following person: Name Number of Shares as my/our proxy to attend, speak and vote for me/us and on my/our behalf at the Annual General Meeting of the Company to be held at 1 |
|
| April 17, 2018 |
Exhibit 99.1 17 April 2018 Motif Bio plc (“Motif Bio” or the “Company”) Posting of UK Annual Report and Accounts & Notice of AGM Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its 2017 UK Annual Report and Accounts and notice of its Annual General Meeting have been posted to shareholders and will short |
|
| April 17, 2018 |
Notice of Annual General Meeting Exhibit 99.4 Notice of Annual General Meeting THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to what action you should take, you are recommended to seek financial advice from your stockbroker or other independent adviser authorized under the Financial Services and Market Act 2000. If you have recently sold or transferred all of your shares in Motif Bio |
|
| April 17, 2018 |
Exhibit 99.3 Dear Shareholder, NOTICE OF AGM / ANNUAL REPORT & ACCOUNTS We hereby notify you that the Annual Report and Financial Statements for the year ended 2017, Notice of the Annual General Meeting to be held on 19 June 2018, and the form of proxy for the Annual General Meeting are now available on the Company’s website www.motifbio.com under the tab https://www.motifbio.com/aim-investors/. Y |
|
| April 17, 2018 |
Exhibit 99.2 17 April 2018 Motif Bio plc (“Motif Bio” or the “Company”) Posting of UK Annual Report and Accounts & Notice of AGM Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its 2017 UK Annual Report and Accounts and notice of its Annual General Meeting have been posted to shareholders and will short |
|
| April 17, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: April 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| April 10, 2018 |
Motif Bio Reports Fiscal Year 2017 Results Exhibit 99.1 Motif Bio Reports Fiscal Year 2017 Results New York, NY, April 10, 2018 - Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2017. Dr. Graham Lumsden, Chief Executive Officer, said: “Motif Bio made tremendous progress in 2017, accomplishing several |
|
| April 10, 2018 |
Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio Reports Fiscal Year 2017 Results Exhibit 99.2 10 April 2018 Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio Reports Fiscal Year 2017 Results Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2017. Dr. Graham Lumsden, Chief Executive Officer, said: “Motif Bio made tremendous progress in |
|
| April 10, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: April 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal exec |
|
| April 10, 2018 |
CONSULTING AGREEMENT Effective Date: February 2, 2018 Exhibit 4.25 CONSULTING AGREEMENT Effective Date: February 2, 2018 THIS CONSULTING AGREEMENT (this “Agreement”) is entered into by and between Motif Biosciences, Inc., a Delaware corporation (the “Company”), and Robert Dickey IV, an individual (“Consultant”), as of the date set forth above (the “Effective Date”). WHEREAS, the Consultant was previously the Chief Financial Officer of the Company (“C |
|
| April 10, 2018 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Dr. Graham Lumsden, certify that: 1. I have reviewed this annual report on Form 20-F of Motif Bio plc (the “Company”) for the fiscal year ended December 31, 2017; 2. Based on my knowledge, this annual |
|
| April 10, 2018 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Motif Bio plc (the “Company”) on Form 20-F for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof, I, Jonathan Gold, Chief Financial |
|
| April 10, 2018 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-222042, 333-222614) of Motif Bio plc of our report dated May 16, 2016 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LLP Aberdeen, United Kingdom April 10, 2018 |
|
| April 10, 2018 |
CONSENT OF BAL PHARMA CONSULTING, LLC Exhibit 15.3 CONSENT OF BAL PHARMA CONSULTING, LLC BAL Pharma Consulting, LLC hereby consents to all references to the market research survey it was commissioned to prepare on behalf of Motif Bio plc entitled “Assessment of Iclaprim Commercial Opportunity in the Gram Positive Antibiotic Hospital Market” and to the results of such survey (collectively, the “BAL Information”) included in this Annual |
|
| April 10, 2018 |
EX-4.22 3 a18-73371ex4d22.htm EX-4.22 Exhibit 4.22 EXECUTION COPY THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HER |
|
| April 10, 2018 |
Exhibit 4.21 EXECUTION COPY LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of November 14, 2017 and is entered into by and among MOTIF BIOSCIENCES INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to herein as the “Borrower”), the several banks and other financial institutions or entities from time to time par |
|
| April 10, 2018 |
Exhibit 4.24 EXECUTION COPY STOCK PLEDGE AGREEMENT This Stock Pledge Agreement (this “Agreement”) is entered into as of November 14, 2017, by and between HERCULES CAPITAL, INC., as administrative agent and collateral agent (in such capacity, “Agent”) for a syndicate of secured parties (together with Agent, collectively, “Secured Parties”) and MOTIF BIO PLC, a public limited company organized under |
|
| April 10, 2018 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-222042, 333-222614) of Motif Bio plc of our report dated April 10, 2018 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LLP Florham Park, New Jersey, United States of America |
|
| April 10, 2018 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Motif Bio plc (the “Company”) on Form 20-F for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof, I, Dr. Graham Lumsden, Chief Exec |
|
| April 10, 2018 |
MTFB / Motif Bio plc ADRs 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 10, 2018 |
Exhibit 15.4 CONSENT OF JMI LABORATORIES JMI Laboratories hereby consents to all references to the worldwide microbiological survey (protocol #15-MOT-01) it was commissioned to prepare on behalf of Motif Bio plc and to the results of such survey (collectively, the “JMI Information”) included in this Annual Report on Form 20-F of Motif Bio plc for the year ending December 31, 2017, and to all refer |
|
| April 10, 2018 |
CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE Exhibit 4.26 CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE THIS CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE (the “Agreement”) is made and entered into by and between Robert Dickey IV (“Dickey”) and Motif BioSciences, Inc. (the “Company”) (collectively, the “Parties”). WHEREAS, Dickey was employed by the Company pursuant to an employment agreement, dated January 16, 2017 (the “Employment Agreemen |
|
| April 10, 2018 |
Exhibit 15.5 CONSENT OF IHMA LABORATORIES IHMA Laboratories hereby consents to all references to the US and Europe microbiological survey it was commissioned to prepare on behalf of Motif Bio plc and to the results of such survey (collectively, the “IHMA Information”) included Annual Report on Form 20-F of Motif Bio plc for the year ending December 31, 2017, and to all references to IHMA Laborator |
|
| April 10, 2018 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jonathan Gold, certify that: 1. I have reviewed this annual report on Form 20-F of Motif Bio plc (the “Company”) for the fiscal year ended December 31, 2017; 2. Based on my knowledge, this annual repo |
|
| April 10, 2018 |
Exhibit 4.23 EXECUTION COPY REGISTRATION AGREEMENT THIS REGISTRATION AGREEMENT is entered into as of November 14, 2017 by and between Motif Bio Plc, a public limited company incorporated in England and Wales (the “Company”), and Hercules Capital, Inc., a Maryland corporation (“Hercules”). RECITALS WHEREAS, in connection with the transactions contemplated by that certain Loan and Security Agreement |
|
| April 3, 2018 |
Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update EXHIBIT 99.1 Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the initiation of a rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FD |
|
| April 3, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) 6-K 1 f6k040218.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Add |
|
| March 20, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K/A (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: March 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10017 (Address of principal ex |
|
| March 20, 2018 |
EXHIBIT 99.1 Motif Bio Update on NDA Submission for Iclaprim NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and timeline for submission of its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its targeted, Gr |
|
| March 20, 2018 |
Motif Bio Update on NDA Submission for Iclaprim EXHIBIT 99.1 Motif Bio Update on NDA Submission for Iclaprim NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and timeline for submission of its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its targeted, Gr |
|
| March 20, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10017 (Address of principal executive o |
|
| March 19, 2018 |
Motif Bio to present at upcoming investor and scientific conferences EXHIBIT 99.1 Motif Bio to present at upcoming investor and scientific conferences NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) - Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at the following conferences in March. Superbugs & Superdrugs 2018 March 19-20, 2018 London, UK David Hua |
|
| March 19, 2018 |
MTFB / Motif Bio plc ADRs FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Translation of registrant's name into English) 125 Park Avenue 25th Floor New York , New York 10011 (Address of principal executive o |
|
| March 1, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: March 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal exec |
|
| March 1, 2018 |
Motif Bio plc (“Motif Bio” or the “Company”) Grant of share options to senior management Exhibit 99.1 1 March 2018 Motif Bio plc (?Motif Bio? or the ?Company?) Grant of share options to senior management Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 4,750,000 options to purchase ordinary shares of 1 pence each of Motif Bio (?Ordinary Shares?) under the Company |
|
| February 21, 2018 |
Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio to Present Iclaprim Data at ECCMID 2018 Exhibit 99.1 21 February 2018 Motif Bio plc (?Motif Bio? or the ?Company?) Motif Bio to Present Iclaprim Data at ECCMID 2018 ? Phase 3 trial results for REVIVE-2 in patients with ABSSSI ? Potential cost savings opportunities with iclaprim versus vancomycin ? Iclaprim in vitro susceptibility data Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing |
|
| February 21, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: February 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal e |
|
| February 14, 2018 |
MTFB / Motif Bio plc ADRs / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Motif Bio plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 619784101 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 5, 2018 |
Exhibit 99.1 2 February 2018 Motif Bio plc (?Motif Bio? or the ?Company?) Appointment of Jonathan E. Gold as Interim Chief Financial Officer Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Dickey IV has informed the Company of his intention to resign from his role as Chief Financial Officer (CFO) |
|
| February 5, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: February 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal e |
|
| February 2, 2018 |
MTFB / Motif Bio plc ADRs / Invesco Ltd. - MOTIF BIO PLC Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES ACT OF 1934 (Amendment No. 1) Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0.01 per share (Title and Class of Securities) 619784101 (CUSIP Number) Nancy Tomassone Invesco Ltd. 1555 Peachtree Street, N.E., Suite 1800 Atlanta, Georgia 30309 Telephone number: (404) 892-0896 (Name, Address and Tel |
|
| January 29, 2018 |
MTFB / Motif Bio plc ADRs CORRESP MOTIF BIO PLC 125 Park Avenue 25th Floor New York, New York 10011 (646) 880-3050 January 29, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| January 19, 2018 |
Motif Bio Announces Filing of U.S. Shelf Registration Exhibit 99.1 Motif Bio Announces Filing of U.S. Shelf Registration New York, NY, January 19, 2018. Motif Bio? plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has filed a ?universal? shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (the ?SEC?). The filing of a s |
|
| January 19, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: January 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal ex |
|
| January 18, 2018 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on January 18, 2018 Registration No. |
|
| January 5, 2018 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: January 2018 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal ex |
|
| January 5, 2018 |
Exhibit 99.1 5 January 2018 Motif Bio plc (?Motif Bio? or the ?Company?) Motif Bio to participate in panel discussion at upcoming Cantor Antibiotics Summit Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event: Cantor Antibiotics Summit January 17, 2018 Omni |
|
| January 3, 2018 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-222042 PROSPECTUS 1,202,902 American Depositary Shares Each Representing 20 Ordinary Shares Issuable Upon the Exercise of Warrants 11,181,714 Ordinary Shares Issuable Upon the Exercise of Warrants This prospectus relates to (i) the offer and sale by us of 1,202,902 American Depositary Shares, or ADSs, each representing 20 of o |
|
| January 3, 2018 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-222042 PROSPECTUS 11,099,220 Ordinary Shares Including 1,469,040 Ordinary Shares in the Form of 73,452 American Depositary Shares This prospectus relates to the resale of up to 11,099,220 ordinary shares, nominal value of ?0.01 per share of Motif Bio plc, that may be sold from time to time by the selling shareholders named in |
|
| December 28, 2017 |
MOTIF BIO PLC 125 Park Avenue 25th Floor New York, New York 10011 (646) 880-3050 December 28, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| December 22, 2017 |
Motif Bio plc (“Motif Bio” or the “Company”) Motif Bio notes statement from Amphion Innovations Exhibit 99.1 22 December 2017 Motif Bio plc (?Motif Bio? or the ?Company?) Motif Bio notes statement from Amphion Innovations Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement made today via RNS by Amphion Innovations plc (?Amphion?), a substantial shareholder in the Company, relating to the successful |
|
| December 22, 2017 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: December 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal e |
|
| December 21, 2017 |
Exhibit 99.1 21 December 2017 Motif Bio plc (?Motif Bio? or the ?Company?) Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious Diseases ? Iclaprim met the primary endpoint ? Iclaprim was well tolerated in the study ? Additional data from the previously announced topline results are included in the publication Motif Bio plc (AIM/NASDAQ: MTF |
|
| December 21, 2017 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: December 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal e |
|
| December 14, 2017 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: December 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal e |
|
| December 14, 2017 |
Motif Bio plc (“Motif Bio” or the “Company”) Filing of SEC Form F-3 Exhibit 99.1 14 December 2017 This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws or any such state or jurisdiction. Motif Bio plc (?Motif Bio? or the |
|
| December 13, 2017 |
Table of Contents As filed with the Securities and Exchange Commission on December 13, 2017 Registration No. |
|
| November 15, 2017 |
MTFB / Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: November 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal e |
|
| November 15, 2017 |
Exhibit 99.1 15 November 2017 The information contained within this announcement is deemed by Motif Bio plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain Motif Bio plc (?Motif Bio? or the ?Compan |
|
| October 6, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: October 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal ex |
|
| October 6, 2017 |
Exhibit 99.1 6 October 2017 Motif Bio plc (?Motif Bio? or the ?Company?) Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017? 1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Fibrosis Patients 2. Iclaprim Demonstrates Potent In Vitro Suppression of Exotoxins in MRSA Isolates Motif Bio plc (AIM/NASDAQ: MTFB), a |
|
| October 4, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: October 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal ex |
|
| October 4, 2017 |
Exhibit 99.1 4 October 2017 The information contained within this announcement is deemed by Motif Bio plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Motif Bio plc (?Motif Bio? or the ?Company |
|
| September 29, 2017 |
Exhibit 99.1 September 29, 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION The information contained within this announcement is deemed by Motif Bio plc to constitute inside information as stipulated under the Market Abu |
|
| September 29, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: September 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal |
|
| September 25, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: September 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal |
|
| September 25, 2017 |
Motif Bio plc (“Motif” or the “Group”) Holding(s) in the Company Exhibit 99.1 25 September 2017 Motif Bio plc (?Motif? or the ?Group?) Holding(s) in the Company Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 22 September 2017 by Amphion Innovations plc (?Amphion?) that a total of 4,390,000 ordinary shares in the Company had been sold in respect of a partial |
|
| September 15, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) 6-K 1 a17-2214216k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: September 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 1 |
|
| September 15, 2017 |
Exhibit 99.1 15 September 2017 Motif Bio plc (Motif Bio or the Company) Motif Bio announces iclaprim granted Orphan Drug Designation by US FDA for treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the US Food and Drug |
|
| September 8, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: September 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal |
|
| September 8, 2017 |
Exhibit 99.1 08 September 2017 Motif Bio plc (Motif Bio or the Company) Motif Bio to Host Investor and Analyst Event on September 20, 2017 in New York Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will host an Investor and Analyst Event on Wednesday, September 20, 2017, in New York fro |
|
| September 6, 2017 |
MTFB / Motif Bio plc ADRs / Morgan Richard C E - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0. |
|
| September 6, 2017 |
Motif Bio plc ADRs SC 13G (Passive Acquisition of More Than 5% of Shares) SC 13G 1 a17-213432sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0.01 per share (Title of Class of Securities) 619784 101 (CUSIP Number) December 31, 2016 (Date of Event That Requires Filing of this Statement) Check the appropriate box to design |
|
| September 6, 2017 |
Motif Bio plc ADRs SC 13G (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value ?0. |
|
| August 31, 2017 |
Exhibit 99.1 31 August 2017 Motif Bio plc (?Motif? or the ?Company?) Motif Bio to present at upcoming investor and scientific conferences Motif Bio plc (AIM/NASDAQ: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will present at the following conferences in September. Rodman & Renshaw 19th Annual Global Investment C |
|
| August 31, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: August 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal exe |
|
| August 9, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: August 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal exe |
|
| August 9, 2017 |
EX-99.1 2 a17-198951ex99d1.htm EX-99.1 Exhibit 99.1 9 August 2017 Motif Bio plc (“Motif” or the “Company”) Motif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phase Motif Bio plc (AIM/NASDAQ: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the last patient has completed the treatment phase in REVIVE-2 |
|
| July 18, 2017 |
Motif Bio plc (“Motif” or the “Company”) Amendment to Amphion Innovations Consultancy Agreement Exhibit 99.1 18 July 2017 Motif Bio plc (?Motif? or the ?Company?) Amendment to Amphion Innovations Consultancy Agreement Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has amended the terms of its consultancy agreement with Amphion Innovations plc. On April 1, 2015, the Group entered into a consultancy agreem |
|
| July 18, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: July 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| July 6, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: July 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| July 6, 2017 |
MOTIF BIO TO PRESENT THREE POSTERS AT IDWEEK 2017 Exhibit 99.1 MOTIF BIO TO PRESENT THREE POSTERS AT IDWEEK 2017 NEW YORK, July 6, 2017 (GLOBE NEWSWIRE) ? Motif Bio plc (NASDAQ: MTFB; AIM: MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that three abstracts have been accepted for poster presentations at the Infectious Diseases Week Annual Meeting in San Diego 4-8 October 2017. The |
|
| June 23, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| June 23, 2017 |
Motif Bio Announces Result of General Meeting and Total Voting Rights Exhibit 99.1 Motif Bio Announces Result of General Meeting and Total Voting Rights THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFERING OF ANY SECURITIES. ANY OFFERING OF SECURITIES BY THE COMPANY IS NOT ADDRESSED TO ANY PERSON WITH A REGISTERED ADDRESS IN, OR WHO IS RESIDENT IN, THE UNITED STATES OR ANY U.S. PERSON, AND NO SUCH PERSONS ARE ENTITLED TO PARTICIPATE IN ANY SUCH OFFERING. This announcem |
|
| June 22, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| June 22, 2017 |
Motif Bio Invited to Present at Infectious Diseases Conference Exhibit 99.1 Motif Bio Invited to Present at Infectious Diseases Conference NEW YORK, June 22, 2017 (GLOBE NEWSWIRE) ? Motif Bio plc (NASDAQ: MTFB; AIM: MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that Dr. David Huang, Chief Medical Officer at Motif Bio, has been invited to present a clinical development overview of iclaprim du |
|
| June 16, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| June 16, 2017 |
Motif Bio plc (the “Company”) Results of Annual General Meeting Exhibit 99.1 15 June 2017 Motif Bio plc (the ?Company?) Results of Annual General Meeting Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting of Motif Bio plc held earlier today, all resolutions proposed were duly passed by the shareholders on a poll. The results of the poll, incorporatin |
|
| June 14, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| June 14, 2017 |
Motif Bio to Present at BIO International Convention Exhibit 99.1 Motif Bio to Present at BIO International Convention NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) Motif Bio plc (NASDAQ: MTFB; AIM: MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that the Company will present at BIO 2017 being held at the San Diego Convention Center, 111 West Harbor Drive, San Diego from 19-22 June 2017 |
|
| June 9, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| June 9, 2017 |
Exhibit 99.1 8 June 2017 Motif Bio plc (?Motif Bio? or the ?Company?) Notification of change in holding of significant shareholder Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 7 June 2017 by Aviva plc & its subsidiaries (?Aviva?) that as at 6 June 2017 Aviva?s direct interest in shares in the |
|
| June 6, 2017 |
Exhibit 99.2 Proof 3: 03-06-2017 Motif Bio PLC Form of Proxy I/We ................................................................................................................................................................ (block capitals please) of .................................................................................................................................................. |
|
| June 6, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| June 6, 2017 |
Exhibit 99.1 NOT FOR ONWARD RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA THIS DOCUMENT DOES NOT CONSTITUTE AN OFFERING OF ANY SECURITIES. ANY OFFERING OF SECURITIES BY THE COMPANY IS NOT ADDRESSED TO ANY PERSON WITH A REGISTERED ADDRESS IN, OR WHO IS RESIDENT IN, THE UNITED |
|
| June 2, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execu |
|
| June 2, 2017 |
Motif Bio plc (“Motif Bio” or the “Company”) Result of Placing Exhibit 99.2 2 June 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFERING OF ANY SECURITIES. ANY OFFERING OF SECURITIES BY THE COMPANY IS NOT ADDRESSED TO ANY PERSON WITH A REGISTERED ADDRESS IN, OR WHO IS RESIDENT IN, T |
|
| June 2, 2017 |
Motif Bio plc (Motif Bio or the Company) Proposed Placing to raise approximately £19.4m (US$25m) Exhibit 99.1 2 June 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) DOES NOT CONSTITUTE AN OFFERING OF ANY SECURITIES. ANY OFFERING OF SECURITIES BY THE COMPANY IS NOT ADDRESSED TO ANY PERSON WITH A REGISTERED ADDRESS IN, |
|
| May 18, 2017 |
Exhibit 99.2 18 May 2017 Motif Bio plc (?Motif Bio? or the ?Company?) Publication of UK Annual Report and Accounts & Notice of AGM Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces its 2016 UK Annual Report and Accounts and notice of its Annual General Meeting have been posted to shareholders and will shortly be availabl |
|
| May 18, 2017 |
Publication of UK Annual Report and Accounts & Notice of AGM Exhibit 99.1 Publication of UK Annual Report and Accounts & Notice of AGM NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) ? Motif Bio plc (NASDAQ: MTFB; AIM: MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced its 2016 UK Annual Report and Accounts and notice of its Annual General Meeting have been posted to shareholders and will shortly be av |
|
| May 18, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: May 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execut |
|
| May 10, 2017 |
Motif Bio Appoints Scientific Opinion Leaders to Advisory Board Exhibit 99.1 Motif Bio Appoints Scientific Opinion Leaders to Advisory Board NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) ? Motif Bio plc (NASDAQ: MTFB; AIM: MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr.Thomas Lodise, Dr.Thomas Holland and Dr. William O?Riordan to the Clinical Advisory Board. The three new advis |
|
| May 10, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) 6-K 1 a17-1283116k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: May 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 ( |
|
| May 5, 2017 |
Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director Exhibit 99.1 Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director NEW YORK, May 5, 2017 (GLOBE NEWSWIRE) Motif Bio plc (NASDAQ: MTFB; AIM: MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Craig T. Albanese to the Companys Board as Non-Executive Director with immediate effect. Dr. Albanese has 25 |
|
| May 5, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: May 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execut |
|
| May 1, 2017 |
Motif Bio Reports Year-End 2016 Financial Results Exhibit 99.1 Motif Bio Reports Year-End 2016 Financial Results NEW YORK, May 1, 2017 (GLOBE NEWSWIRE) ? Motif Bio plc (NASDAQ: MTFB; AIM: MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. ?Motif Bio made significant progress in 2016 towards our goal of bringing our novel antibio |
|
| May 1, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: May 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor New York, New York 10011 (Address of principal execut |
|
| May 1, 2017 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 18, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: April 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor, Suite 2622 New York, New York 10011 (Address of pr |
|
| April 18, 2017 |
Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study Exhibit 99.1 Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study ? Iclaprim met the primary endpoint ? Iclaprim was well tolerated in the study ? Data from the second Phase 3 ABSSSI Trial, REVIVE-2, expected in the second half of 2017 ? NDA submission expected in the first half of 2018 Company to host conference call today at 8:00 am EDT, 1:00 pm BST NEW YORK, April 18 |
|
| April 12, 2017 |
Exhibit 99.1 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Motif Bio plc 2. Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may result in the acquisiti |
|
| April 12, 2017 |
Motif Bio plc ADRs 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: April 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor, Suite 2622 New York, New York 10011 (Address of pr |
|
| April 12, 2017 |
Exhibit 99.2 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Motif Bio plc 2. Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may result in the acquisiti |
|
| February 8, 2017 |
MOTIF BIO 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: February 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor, Suite 2622 New York, New York 10011 (Address of |
|
| February 8, 2017 |
Motif Bio plc (“Motif Bio” or the “Company”) Director and PDMR dealing - grant of options Exhibit 99.1 8 February 2017 This announcement contains inside information Motif Bio plc (Motif Bio or the Company) Director and PDMR dealing - grant of options Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted options to purchase ordinary shares of 1 pence each of Motif Bio (Ordinary Sh |
|
| January 30, 2017 |
Motif Bio Phase 3 clinical trial finishes patient treatment phase Exhibit 99.1 Motif Bio Phase 3 clinical trial finishes patient treatment phase NEW YORK, January 30, 2017 (GLOBE NEWSWIRE) ? Motif Bio plc (Motif)(NASDAQ: MTFB), (NASDAQ: MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the saf |
|
| January 30, 2017 |
MOTIF BIO 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: January 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor, Suite 2622 New York, New York 10011 (Address of |
|
| January 17, 2017 |
Appointment of Chief Financial Officer Exhibit 99.1 Appointment of Chief Financial Officer NEW YORK, January 17, 2017 (GLOBE NEWSWIRE) Motif Bio plc (Motif)(NASDAQ: MTFB), (NASDAQ: MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announces that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional with senior leadership expe |
|
| January 17, 2017 |
MOTIF BIO 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: January 2017 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of registrant as specified in its charter) 125 Park Avenue 25th Floor, Suite 2622 New York, New York 10011 (Address of |
|
| December 22, 2016 |
Exhibit 99.2 Motif Bio plc Announces Conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights NEW YORK, December 22, 2016 (GLOBE NEWSWIRE) ?Motif Bio plc (Motif)(NASDAQ: MTFB), (NASDAQ: MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics announced, that it has issued, in aggregate, 14,510,770 new ordinary shares in the Company (?O |
|
| December 22, 2016 |
MOTIF BIO 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of: December 2016 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of Registrant as specified in its charter) 125 Park Avenue 25th Floor, Suite 2622 New York, New York 10011 (Address of |
|
| December 22, 2016 |
Motif Bio plc (“Motif Bio” or the “Company”) Result of GM Exhibit 99.1 21 December 2016 Motif Bio plc (Motif Bio or the Company) Result of GM Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that all resolutions put to shareholders at the Companys General Meeting held earlier today were duly passed. For further information please contact: Motif Bio plc [email protected] Gr |
|
| December 5, 2016 |
Motif Bio plc (Motif Bio or the Company) Exhibit 99.1 Motif Bio plc (Motif Bio or the Company) 5 December 2016 PUBLICATION OF CIRCULAR AND NOTICE OF GENERAL MEETING Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on Friday 2 December 2016 it sent to Shareholders a circular and notice of General Meeting to be held at the offices of Reed Smith LLP at T |
|
| December 5, 2016 |
MOTIF BIO 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of: December 2016 Commission File Number: 001-37847 MOTIF BIO PLC (Exact name of Registrant as specified in its charter) 125 Park Avenue 25th Floor, Suite 2622 New York, New York 10011 (Address of |
|
| November 29, 2016 |
MTFB / Motif Bio plc ADRs / Invesco Ltd. - MOTIF BIO PLC 11292016 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES ACT OF 1934 Motif Bio plc (Name of Issuer) Ordinary Shares, par value £0.01 per share (Title and Class of Securities) 619784101 (CUSIP Number) Nancy Tomassone Invesco Ltd. 1555 Peachtree Street, N.E., Suite 1800 Atlanta, Georgia 30309 Telephone number: (404) 892-0896 (Name, Address and Telephone Number of P |
|
| November 21, 2016 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(B)(4) Registration No. |
|
| November 17, 2016 |
MOTIF BIO PLC FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated November 17, 2016 Relating to Preliminary Prospectus dated November 14, 2016 Registration No. |
|
| November 15, 2016 |
Motif Bio plc 125 Park Avenue 25th Floor, Suite 2622 New York, NY 10011 United States November 16, 2016 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| November 15, 2016 |
November 16, 2016 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: MOTIF BIO PLC Registration Statement on Form F-1 (Registration No. 333-212491) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (?Wainwright?), as managing underwriter for the referenced offering, hereby concurs in the reques |
|
| November 14, 2016 |
F-1/A 1 a2230255zf-1a.htm F-1/A Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on November 14, 2016 Registration No. 333-212491 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 10 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1 |
|
| November 14, 2016 |
599 Lexington Avenue New York, NY 10022-7650 +1 212 521 5400 Fax +1 212 521 5450 reedsmith. |
|
| November 4, 2016 |
QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on November 4, 2016 Registration No. |
|
| November 4, 2016 |
Exhibit 1.1 AMERICAN DEPOSITARY SHARES, EACH REPRESENTING 20 ORDINARY SHARES, ?0.01 PAR VALUE, AND WARRANTS TO PURCHASE AMERICAN DEPOSITARY SHARES MOTIF BIO PLC UNDERWRITING AGREEMENT , 2016 H.C. Wainwright & Co., LLC As Representative of the Several Underwriters, if any, listed on Schedule I hereto 430 Park Avenue, 4th Floor New York, New York 10022 Ladies and Gentlemen: Motif Bio plc, a public l |
|
| November 4, 2016 |
Exhibit 4.3 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of , 2016 (the ?Issuance Date?) between Motif Bio plc, a company incorporated under the laws of England and Wales (the ?Company?), and The Bank of New York Mellon (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated , 2016, betwee |
|
| November 4, 2016 |
Exhibit 4.5 MOTIF BIO PLC WARRANT INSTRUMENT DATED: [?] 2016 Reed Smith LLP The Broadgate Tower 20 Primrose Street London EC2A 2RS Phone: +44 (0) 20 3116 3000 Fax: +44 (0) 20 3116 3999 DX1066 City / DX18 London reedsmith.com CONTENTS 1 DEFINITIONS AND INTERPRETATION 2 2 SUBSCRIPTION RIGHTS 5 3 WARRANT CERTIFICATES 6 4 EXERCISE OF WARRANTS 7 5 BENEFICIAL OWNERSHIP LIMITATION 10 6 CASHLESS EXERCISE |
|
| November 1, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 MOTIF BIO PLC (Exact name of registrant as specified in its charter) United Kingdom Not Applicable (State of incorporation or organization) (I.R.S. Employer Identification No.) 125 Park Avenue 25 |
|
| October 31, 2016 |
Motif Bio plc (?Motif Bio? or the ?Company?) Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Registration No. 333-212491 October 31, 2016 31 October 2016 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Motif Bio plc (?Motif Bio? or the ?Company?) UPDATE ON TIM |
|
| October 31, 2016 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on October 31, 2016 Registration No. |
